KYN-101 is a potent, selective and orally active AHR inhibitor. KYN-101 decreases the CYP1A1 mRNA expression. KYN-101 shows anti-cancer activity. In Vitro KYN-101 (0.5, 1 µM; 24 h) decreases the CYP1A1 mRNA expression in IDO high samples. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo KYN-101 (10 mg/kg; p.o.; daily for 12 days) shows anti-cancer activity in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-8 weeks, C57BL/6J mice (B16IDO tumor-bearing mice) Dosage: 10 mg/kg Administration: P.o.; daily for 12 days Result: Reduced tumor growth in B16IDO tumor-bearing mice and combination of KYN-101 and anti-PD-1 led to improved tumor growth delay and extended survival in CT26 models. Form:Solid